Pills Join the Picture: The First Oral GLP-1 Medications for Weight Management

For years, the most talked-about weight-loss medications in the GLP-1 family have been weekly injections. In the past few months that changed: the FDA has now approved two daily pills for chronic weight management. This guide explains what is new, what a major trial of one of them reported, and what remains unknown. It is general education, not medical advice, and it does not recommend any product, dose or provider.

What is new

According to news reports, the first oral GLP-1 medication for overweight or obesity, a form of semaglutide, was approved by the FDA on December 22, 2025. A second oral medication, orforglipron, a small-molecule drug that works on the same hormone pathway, was approved on April 1, 2026. Both are approved for adults with obesity, or with overweight and at least one weight-related health condition, and both are meant to be used together with a reduced-calorie diet and more physical activity. Reports say orforglipron can be taken without restrictions on food or water, which is one way it differs from earlier oral versions.

A closer look at the large orforglipron trial

The main trial, called ATTAIN-1, was published in the New England Journal of Medicine in 2025. It enrolled 3,127 adults with obesity and without diabetes, who were randomly assigned to one of three doses of the pill or to a placebo for 72 weeks.

• Average weight change at 72 weeks: about 7.5%, 8.4% and 11.2% lower with the three doses, compared with 2.1% lower with placebo.
• Reaching a 10 percent loss or more: 54.6% of people on the highest dose, compared with 12.9% on placebo.
• Stopping because of side effects: between 5.3% and 10.3% of people taking the pill, compared with 2.7% on placebo. The most common side effects were mild to moderate stomach and digestive problems.

You may also see a figure of 12.4% for the highest dose. That number comes from a second way of analyzing the same trial, which looks only at people who stayed on the medication. The 11.2% figure counts everyone as they were originally assigned. Neither is wrong, but they answer slightly different questions, and the second is the more cautious one.

Why a pill matters to many people

• No injections. Some people are uncomfortable with needles, and a daily pill removes that barrier.
• More options. More choices can make it easier for a person and a clinician to find something that fits.

Cautions worth keeping in mind

• Averages are not promises. Some participants lost far more than the group average and some lost far less.
• Separate trials are not direct comparisons. Numbers from separate trials, with different groups and designs, cannot be lined up fairly against the injectable medications.
• The questions that apply to injections still apply. See our guides to side effects in the big GLP-1 trials, stopping a GLP-1 medication and muscle loss.
• Where a medication comes from matters. Our guide to how these medications are regulated explains why.

Talking it over

If you are curious about any prescription medication for weight, the best next step is a conversation with a clinician who knows your health history, your other medications and your goals. A new option is not automatically the right one for you, and not having a pill is not a drawback.

In summary

The arrival of oral GLP-1 medications widens the choices for people with obesity, and the large trial of one of them showed meaningful average weight loss over 72 weeks, along with the digestive side effects familiar from this drug family. The longer-term picture is still being filled in.

Sources

• Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (ATTAIN-1). New England Journal of Medicine, 2025;393(18):1796-1806.
• Healio, “FDA approves orforglipron, an oral GLP-1 for adults with obesity,” April 1, 2026 (approval date, indication and the earlier oral approval).
• Patient Care Online and Consultant360 news reports on the April 2026 FDA approval (approval details and the 12.4% efficacy-estimand figure).